Optimal threshold of stimulated serum thyroglobulin level for ¹⁸F-FDG PET/CT imaging in patients with thyroid cancer

Abstract

This study was to explore the optimal threshold of thyroid-stimulating hormone (TSH)-stimulated serum thyroglobulin (s-Tg) for patients who were to receive ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/CT scan owing to clinical suspicion of differentiated thyroid cancer (DTC) recurrence but negative post-therapeutic ¹³¹I whole-body scan (¹³¹I-WBS). A total of 60 qualified patients underwent PET/CT scanning from October 2010 to July 2014. The receiver operating characteristic (ROC) curve analyses showed that s-Tg levels over 49 μg/L led to the highest diagnostic accuracy of PET/CT to detect recurrence, with a sensitivity of 89.5% and a specificity of 90.9%. Besides, bivariate correlation analysis showed positive correlation between s-Tg levels and the maximum standardized uptake values (SUVmax) of ¹⁸F-FDG in patients with positive PET/CT scanning, suggesting a significant influence of TSH both on Tg release and uptake of ¹⁸F-FDG. So, positive PET/CT imaging is expected when patients have negative ¹³¹I-WBS but s-Tg levels over 49 μg/L.

Keywords

¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) / positron emission tomography/computed tomography (PET/CT) / differentiated thyroid cancer (DTC) / post-therapeutic ¹³¹I whole-body scan (¹³¹I-WBS) / serum thyroglobulin (Tg) / thyroid-stimulating hormone (TSH)

References

[1] CooperDS, DohertyGM, HaugenBR, et al. . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11): 1167-1214 PMID: 19860577

[2] FreudenbergLS, AntochG, FrillingA, et al. . Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDGPET. Eur J Nucl Med Mol Imaging, 2008, 35(5): 950-957 PMID: 18193222

[3] LusterM, KargesW, ZeichK, et al. . Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid, 2010, 20(5): 527-533 PMID: 20450432

[4] Vera P, Kuhn-Lansoy C, Edet-Sanson A, et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid, 2010,20(1):15–23

[5] SeoJH, LeeSW, AhnBC, et al. . Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol, 2010, 72(4): 558-563

[6] NaSJ, Yoo IeRO J, et al. . Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/ computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131) I whole body scan: evaluation by thyroglobulin level. Ann Nucl Med, 2012, 26(1): 26-34 PMID: 21971605

[7] VuralGU, AkkasBE, ErcakmakN, et al. . Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med, 2012, 37(10): 953-959 PMID: 22899202

[8] Van DijkD, PlukkerJT, PhanHT, et al. . 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin. Thyroid, 2013, 23(8): 1003-1009 PMID: 23517405

[9] TrybekT, KowalskaA, LesiakJ, et al. . The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Nucl Med Rev Cent East Eur, 2014, 17(2): 87-93 PMID: 25088108

[10] SalvatoriM, BiondiB, RufiniV. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/ computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol, 2015, 173(3): R115-R130 PMID: 25947140

[11] PetrichT, BörnerAR, OttoD, et al. . Influence of rhTSH on [18F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med, 2002, 29(5): 641-647

[12] MoogF, LinkeR, MantheyN, et al. . Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med, 2000, 41(12): 1989-1995 PMID: 11138683

[13] ChinBB, PatelP, CohadeC, et al. . Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2004, 89(1): 91-95 PMID: 14715833

[14] MaC, XieJ, LouY, et al. . The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol, 2010, 163(2): 177-183 PMID: 20484385

[15] LuCT, CaoSS, WangW. The influence of TSH expression on the diagnotic efficiency of 18F-FDG PET/CT in the detection of recurrences/metastases of dedifferentiated thyroid carcinoma. Chin J Surg Onco, 2013, 5: 79-81

[16] PadovaniRP, RobenshtokE, BrokhinM, et al. . Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid, 2012, 22(8): 778-783 PMID: 22780333